What’s Next for Nektar Therapeutics?
Nektar Therapeutics (NASDAQ: NKTR) has a lot on its plate. The company's advancing its lead drug candidate, NKTR-181, to the FDA for use in chronic pain and its pipeline crisscrosses immuno-oncology and immunology. Shares of Nektar Therapeutics have been on a roll lately, but can its winning streak continue rewarding investors?
In this clip from The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes and Todd Campbell explain why investors are flocking to include this biotech stock in portfolios.
A full transcript follows the video.
Source: Fool.com
Nektar Therapeutics Aktie
1,25 €
3,71 %
Die Community sieht Nektar Therapeutics leicht positiv: Mehr Buy- als Sell-Einschätzungen.
Ein prognostiziertes Kursziel von 2 € für Nektar Therapeutics zeigt ein Potenzial von über 50% im Vergleich zum aktuellen Kurs von 1.25 €.
